# TACHEM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tachem

- Industry: Materials
- Headquarters: Chengdu, China
- Website: www.cdthchem.com
- Total disclosed funding: $42M
- Latest round: Series A (Nov 29, 2023)
- Investors on record: 8

## About

Established in 2013 and based in Chengdu, China, TACHEM is a biotechnology enterprise engaged in the research, development, production, and sales of protected amino acid series products. The company is headquartered in Chengdu, and established a wholly-owned subsidiary in Lanzhou in 2020, with three standardized plants of more than 1,000 square meters, with an annual output of more than 200 tons, for use as a production base. It has passed the certification of ISO9001:2015 Quality Management System, and was certified as a Specialized and Innovative Small and Medium-sized Enterprises in Sichuan Province in 2022. In November 2023, it raised approximately CNY 100 million in series A+ funding.

The company mainly produces chemical raw materials, and currently possesses the production technology of more than 1,000 protected amino acids and non-natural amino acid series products and is capable of industrialized production, the specific products include Fmoc-Ala-OH-H2O, Fmoc-Aib-OH, fragment peptide series, and amino acid (linker) resins and so on. The company also possesses preparative chromatography as well as reactors of different sizes ranging from 50L to 5000L and other related equipments, which allow it to make customized products in various batches according to customers' needs, including customized synthesis of various impurities.

The company will use the series A+ funding to accelerate the company's 240 mu of Phase II plant production and 500 mu of Phase III plant construction, with a plan to achieve 1,000 mu of Phase I, II and III plant production in 2025.

## Funding rounds

- Series A, Nov 29, 2023, $42M — Qiming Venture Partners, CITIC Goldstone Fund Management, CITIC Securities, GF Xinde Investment, HighLight Capital, Grandway Capital, Sinopharm-CICC Capital, GL Ventures

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- CITIC Goldstone Fund Management (https://capitalatlas.ai/funds/citic-goldstone-fund-management) — Series A
- CITIC Securities — Series A
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A
- Grandway Capital (https://capitalatlas.ai/funds/grandway-capital) — Series A
- Sinopharm-CICC Capital (https://capitalatlas.ai/funds/sinopharm-cicc-capital) — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A